Adalimumab
- Generic Name
- Adalimumab
- Brand Names
- Amjevita, Cyltezo, Humira, Hyrimoz, Yusimry, Hulio, Hefiya, Libmyris, Imraldi, Amsparity, Idacio, Hukyndra, Amgevita, Yuflyma
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 331731-18-1
- Unique Ingredient Identifier
- FYS6T7F842
- Background
Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor. It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA. This drug is frequently known as Humira. It is produced by recombinant DNA technology usi...
- Indication
Adalimumab is indicated for the following conditions:
Adalimumab has also been used off-label to treat Pyoderma gangrenosum.
- Associated Conditions
- Ankylosing Spondylitis (AS), Hidradenitis Suppurativa (HS), Moderate to Severe Chronic Plaque Psoriasis, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Crohn's Disease, Moderately to Severely Active Ulcerative Colitis, Non-infectious Intermediate, Posterior and Panuveitis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Pyoderma Gangrenosum
- Associated Therapies
- -
Extension Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
- First Posted Date
- 2008-03-28
- Last Posted Date
- 2008-03-28
- Lead Sponsor
- Abbott
- Target Recruit Count
- 32
- Registration Number
- NCT00645892
Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis
- Conditions
- Interventions
- First Posted Date
- 2008-03-28
- Last Posted Date
- 2008-03-28
- Lead Sponsor
- Abbott
- Target Recruit Count
- 315
- Registration Number
- NCT00646386
Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
- First Posted Date
- 2008-03-28
- Last Posted Date
- 2008-03-28
- Lead Sponsor
- Abbott
- Target Recruit Count
- 137
- Registration Number
- NCT00646191
Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
- First Posted Date
- 2008-03-28
- Last Posted Date
- 2008-03-28
- Lead Sponsor
- Abbott
- Target Recruit Count
- 148
- Registration Number
- NCT00645814
Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy
- Conditions
- Interventions
- First Posted Date
- 2008-03-28
- Last Posted Date
- 2008-03-28
- Lead Sponsor
- Abbott
- Target Recruit Count
- 102
- Registration Number
- NCT00646178
Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
- First Posted Date
- 2008-03-28
- Last Posted Date
- 2008-03-28
- Lead Sponsor
- Abbott
- Target Recruit Count
- 148
- Registration Number
- NCT00645905
A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2007-10-29
- Last Posted Date
- 2013-01-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 386
- Registration Number
- NCT00550446
- Locations
- 🇺🇦
Pfizer Investigational Site, Zaporizhzhia, Ukraine
Adalimumab (Humira) in the Treatment of Refractory Non-infectious Uveitis
- First Posted Date
- 2007-09-06
- Last Posted Date
- 2012-04-11
- Lead Sponsor
- Oregon Health and Science University
- Target Recruit Count
- 31
- Registration Number
- NCT00525902
- Locations
- 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
Endoscopic Ultrasound (EUS) Guided Treatment With Humira for Crohn's Perianal Fistulas
- Conditions
- Interventions
- First Posted Date
- 2007-08-16
- Last Posted Date
- 2017-04-21
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 21
- Registration Number
- NCT00517296
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.